Previous 10 | Next 10 |
LOS ANGELES, April 25, 2024 (GLOBE NEWSWIRE) -- via IBN – Nutriband Inc. (NASDAQ: NTRB) , a pharmaceutical company with a specific focus on transdermal technologies, today announces it has selected IBN , a multifaceted financial news and publishing company for private and publi...
Nutriband (NASDAQ: NTRB, NTRBW) , a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has closed an $8.4 million private placement to fund the commercial development program for its lead product, AVERSA(TM) Fentanyl. AVERSA Fentanyl ha...
Pegasystems Inc. (PEGA) is expected to report $0.2 for Q1 2024 Masco Corporation (MAS) is expected to report $0.87 for Q1 2024 Avery Dennison Corporation (AVY) is expected to report $2.15 for Q1 2024 Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A...
Private Placement of $8.4 million has closed and will fund the commercial development of lead product AVERSA Fentanyl to NDA filing Nutriband working to complete the commercial scale-up prior to performing the pivotal laboratory assessment and clinical study required for FDA approval AV...
Fentanyl is a potent opioid that is associated with a significant risk of abuse and overdose, contributing to a major drug crisis in the United States Fentanyl has legitimate medical uses in managing severe and chronic pain in medical settings such as hospitals and surgical procedures NTRB is...
Nutriband (NASDAQ: NTRB, NTRBW) today announced that following its engagement by Fit For Life Group (“FFL”), a major brand license holder, on April 19, 2024, the companies fully executed an exclusive supplier agreement for FFL’s new product launch under one of its top brands...
2024-04-23 07:43:37 ET More on Nutriband Financial information for Nutriband Read the full article on Seeking Alpha For further details see: Nutriband signs exclusive supplier agreement with Fit for Life
ORLANDO, FL / ACCESSWIRE / April 23, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today announced that following its engagement by Fit For Life Group (FFL), a major brand license holder, on April 19, 2024, the companies fully executed an exclusive Supplier agreement for FFL's new product l...
Nutriband (NASDAQ: NTRB) , a company engaged in the development of abuse-deterrent pharmaceutical products, has entered into definitive securities purchase agreements. The agreements are for the purchase and sale of up to 2,100,000 shares of common stock, with each share offered at $4 per share. ...
Nutriband is targeting a 505(b)(2) NDA to the FDA for marketing approval of AVERSA™ Fentanyl in Q1 2025 ORLANDO, FL / ACCESSWIRE / April 19, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of abuse deterrent pharmaceutical products announced t...
News, Short Squeeze, Breakout and More Instantly...
Nutriband (NASDAQ: NTRB) , a pharmaceutical company with a special focus on transdermal technologies, is inviting investors to a live webinar. Scheduled for July 25, 2024, at 4:15 p.m. ET, this exclusive event will be hosted by RedChip Companies. During the webinar, Nutriband Chairman and Preside...
ORLANDO, FL / ACCESSWIRE / July 19, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical solutions, is pleased to invite investors to a webinar on July 25, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Nutriband Cha...
Nutriband (NASDAQ: NTRB) , a developer of transdermal pharmaceutical products, has received a Notice of Allowance from the United States Patent and Trademark Office (“USPTO”). According to the announcement, the notice means that the USPTO anticipates granting the trademark registrat...